Evidence map›Paper›PMID 26177202›Full record

ArticlePloS one2015

A Proline-Rich Domain in the Genotype 4 Hepatitis E Virus ORF3 C-Terminus Is Crucial for Downstream V105DLP108 Immunoactivity.

Heng Wang, Fangxiao Ji, Huanbin Liang, Honglang Gu, Zhangyong Ning, Rongchang Liu, Guihong Zhang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Development of new hepatitis E vaccines.Human vaccines & immunotherapeutics · 2018
    Review
  2. Article
  3. ORF3 as a sensitive and specific diagnostic index for hepatitis E.Experimental and therapeutic medicine · 2017
    Article
  4. Article
  5. Hepatitis Vaccines.Vaccines · 2016
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Heng WangCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong Province, 510642, China; Key Laboratory of Comprehensive Prevention and Control for Severe Clinical Animal Diseases of Guangdong Province, Guangzhou, Guangdong Province, 510642, China.
Fangxiao JiCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong Province, 510642, China; MOA Key Laboratory of Animal Vaccine Development, Guangzhou, Guangdong Province, 510642, China.
Huanbin LiangMOA Key Laboratory of Animal Vaccine Development, Guangzhou, Guangdong Province, 510642, China.
Honglang GuMOA Key Laboratory of Animal Vaccine Development, Guangzhou, Guangdong Province, 510642, China.
Zhangyong NingCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong Province, 510642, China; Key Laboratory of Comprehensive Prevention and Control for Severe Clinical Animal Diseases of Guangdong Province, Guangzhou, Guangdong Province, 510642, China.
Rongchang LiuKey Laboratory of Comprehensive Prevention and Control for Severe Clinical Animal Diseases of Guangdong Province, Guangzhou, Guangdong Province, 510642, China.
Guihong ZhangCollege of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong Province, 510642, China; MOA Key Laboratory of Animal Vaccine Development, Guangzhou, Guangdong Province, 510642, China.
Key Laboratory of Guangdong Province · CNSouth China Agricultural University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hepatitis E virus (HEV) is responsible for serious viral hepatitis worldwide. Animals are considered a reservoir of HEV, particularly pigs. While HEV infection in pigs and dogs is always asymptomatic, the virus causes high death rates in patients with pre-existing chronic liver disease and pregnant women in developing countries. HEV open reading frame 2 (ORF2) has been used as a diagnostic target to detect specific antibodies against HEV in serum samples. Recent research has additionally supported the potential utility of the ORF3 protein as a target in serum anti-HEV detection. However, the epitope distribution of ORF3 protein remains ambiguous. In the current study, we showed that continuous amino acid motif, VDLP, at the C-terminus of genotype 4 HEV ORF3 is a core sequence of the ORF3 protein epitope. Moreover, cooperative interaction with upstream elements is essential for its immunoactivity. Three proline residues (P99, P102 and P103) in the upstream proline-rich domain exerted significant effects on the immunocompetence of VDLP. ELISA results revealed that SAPPLPPVVDLP and SAPPLPPVVDLPQLGL peptides containing the identified VDLP epitope display weaker reactions with anti-HEV serum than the commercial ELISA kit. Our collective findings provide valuable information on the epitope distribution characteristics of HEV ORF3 and improve our understanding of the influence of the proline-rich domain on the immunoactivity of downstream amino acids in the C-terminal region.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalBlotting, WesternCell LineEnzyme-Linked Immunosorbent AssayEpitopesFemaleGenotypeHepatitis E virusImmune SeraMice, Inbred BALB CMolecular Sequence DataMutant ProteinsMutationOpen Reading FramesAntibodies, MonoclonalEpitopesImmune SeraMutant ProteinsPeptide LibraryPeptidesProlineRecombinant ProteinsViral Proteins

Identifiers

PMID26177202
PMCPMC4503470
OpenAlexW930483439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.